Supernus Pharmaceuticals said the US FDA has refused to approve a drug and device combination to treat Parkinson’s disease’s movement-related symptoms, sending its shares down 9 per cent in early trading. This is the second time the regulator has denied approval, dealing a blow to the company’s years-long efforts to market its pump-based treatment.